T-ALL
MCID: PRC049
MIFTS: 45

Precursor T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for Precursor T-Cell Acute Lymphoblastic Leukemia:

Name: Precursor T-Cell Acute Lymphoblastic Leukemia 58
T-All 58 53
Precursor T-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor T-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 71
Precursor T-Cell Acute Lymphocytic Leukemia 58
Adult T-Cell Lymphoma/leukemia 71

Characteristics:


Age Of Onset:

Adolescent,Adult 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 32 C91.0
UMLS via Orphanet 72 C1961099
Orphanet 58 ORPHA99861
UMLS 71 C0023493 C1961099

Summaries for Precursor T-Cell Acute Lymphoblastic Leukemia

Orphanet: 58 A rare acute lymphoblastic leukemia characterized by a neoplasm of lymphoblasts committed to the T-cell lineage, involving bone marrow and blood. A value of >25% bone marrow blasts may be used to define leukemia (as opposed to lymphoma) in cases with the presence of a mass lesion in addition to bone marrow involvement. Patients typically present with leukocytosis, and frequently with a large mediastinal or other tissue mass. Lymphadenopathy and hepatosplenomegaly are common.

MalaCards based summary: Precursor T-Cell Acute Lymphoblastic Leukemia, also known as t-all, is related to t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Precursor T-Cell Acute Lymphoblastic Leukemia is TAL1 (TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor), and among its related pathways/superpathways are Immune response Antigen presentation by MHC class II and C-MYB transcription factor network. The drugs Dexrazoxane and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and nervous system

Related Diseases for Precursor T-Cell Acute Lymphoblastic Leukemia

Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 t-cell acute lymphoblastic leukemia 31.6 TLX3 TLX1 TAL1 STIL MYC MYB
2 leukemia, acute lymphoblastic 31.3 TRD TLX3 TLX1 TAL1 PICALM MYC
3 acute leukemia 30.9 TAL1 MLLT10 FLT3 BCR
4 b-lymphoblastic leukemia/lymphoma 30.9 MYC FLT3 CDKN2A BCR ABL1
5 leukemia 30.9 TLX3 TLX1 TAL1 PICALM NUP214 MYC
6 adult acute lymphocytic leukemia 30.8 TLX3 TLX1 TAL1 ABL1
7 acute biphenotypic leukemia 30.7 TLX3 NUP214 MLLT10 FLT3 ABL1
8 hematologic cancer 30.7 PICALM MLLT10 FLT3 BCR ABL1
9 leukemia, chronic myeloid 30.6 TAL1 MYC MYB FLT3 BCR ABL1
10 childhood acute lymphocytic leukemia 30.6 TLX1 FLT3 CDKN2A ABL1
11 childhood t-cell acute lymphoblastic leukemia 30.6 TLX3 TLX1 TAL1 STIL
12 myeloid leukemia 30.5 PICALM NUP214 MYC MYB MLLT10 FLT3
13 childhood leukemia 30.5 MLLT10 FLT3 ABL1
14 leukemia, acute myeloid 30.4 TAL1 PICALM NUP214 MYC MYB MLLT10
15 burkitt lymphoma 30.2 MYC MYB HNRNPH1 CDKN2A BCR
16 wilms tumor 1 30.2 MYC FLT3 CDKN2A ABL1
17 myelodysplastic syndrome 30.1 TRB TRA NUP214 MYC MYB FLT3
18 leukemia, chronic lymphocytic 30.1 MYC MYB FLT3 CDKN2A BCR ABL1
19 lymphoma, non-hodgkin, familial 29.9 TAL1 MYC MYB FLT3 BCR
20 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.4 CDKN2A ABL1
21 vulva basal cell carcinoma 10.4 MYC CDKN2A
22 acute basophilic leukemia 10.4 NUP214 MYB ABL1
23 childhood acute myeloid leukemia 10.4 NUP214 MLLT10 FLT3
24 chronic myelogenous leukemia, bcr-abl1 positive 10.4 BCR ABL1
25 acute erythroid leukemia 10.3 TAL1 MYC MYB FLT3
26 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.3 FLT3 CDKN2A BCR ABL1
27 endocervical adenocarcinoma 10.3 MYC DDX3X CDKN2A
28 lymphoblastic lymphoma 10.3
29 cervical adenoid cystic carcinoma 10.3 MYB CDKN2A
30 chronic leukemia 10.3 FLT3 BCR ABL1
31 mixed phenotype acute leukemia, t/myeloid 10.3 MLLT10 FLT3
32 mantle cell lymphoma 10.3 MYC FLT3 CDKN2A ABL1
33 suppressor of tumorigenicity 3 10.3 MYC CDKN2A
34 leukemia, acute lymphoblastic 3 10.3
35 infratentorial cancer 10.3 MYC DDX3X CDKN2A
36 rasopathy 10.3 MYC FLT3 CDKN2A ABL1
37 leukemia, t-cell, chronic 10.3
38 gastrointestinal stromal tumor 10.3 MYC FLT3 CDKN2A BCR ABL1
39 acute myeloid leukemia with bcr-abl1 10.3 FLT3 ABL1
40 b-cell adult acute lymphocytic leukemia 10.2 BCR ABL1
41 barrett esophagus 10.2 MYC MYB CDKN2A
42 campomelic dysplasia 10.2
43 myeloproliferative disorder, chronic, with eosinophilia 10.2
44 cowden syndrome 1 10.2
45 retinal detachment 10.2
46 lymphoma, hodgkin, classic 10.2
47 sickle cell anemia 10.2
48 aplastic anemia 10.2
49 lymphoma 10.2
50 rapidly involuting congenital hemangioma 10.2

Graphical network of the top 20 diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia:



Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for Precursor T-Cell Acute Lymphoblastic Leukemia

GenomeRNAi Phenotypes related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

25 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.74 TLX1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.74 BCR FLT3 TAL1 TLX1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.74 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.74 TLX1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.74 TAL1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 BCR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.74 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 TLX1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.74 BCR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.74 TLX1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.74 FLT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.74 BCR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.74 TAL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 TLX1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.74 TAL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.74 TLX1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.74 TAL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.74 FLT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.74 TAL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.74 BCR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.74 TAL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.74 BCR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 TLX1

MGI Mouse Phenotypes related to Precursor T-Cell Acute Lymphoblastic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.14 ABL1 BCR CDKN2A DDX3X MLLT10 MYC
2 embryo MP:0005380 10.13 ABL1 CDKN2A CNOT3 DDX3X MLLT10 MYB
3 cellular MP:0005384 10.1 ABL1 BCR CDKN2A CNOT3 DDX3X FLT3
4 liver/biliary system MP:0005370 9.97 ABL1 BCR CDKN2A CNOT3 MLLT10 MYB
5 immune system MP:0005387 9.97 ABL1 BCR CDKN2A CNOT3 FLT3 HNRNPH1
6 hematopoietic system MP:0005397 9.73 ABL1 BCR CDKN2A CNOT3 FLT3 HNRNPH1
7 mortality/aging MP:0010768 9.53 ABL1 BCR CDKN2A CNOT3 DDX3X FLT3

Drugs & Therapeutics for Precursor T-Cell Acute Lymphoblastic Leukemia

Drugs for Precursor T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
4
Ichthammol Approved Phase 3 8029-68-3
5
Tioguanine Approved Phase 3 154-42-7 2723601
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Idarubicin Approved Phase 3 58957-92-9 42890
8
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
9
Aclarubicin Investigational Phase 3 57576-44-0
10
Palifosfamide Investigational Phase 3 31645-39-3 100427
11
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 3 461-06-3
12 Cardiotonic Agents Phase 3
13
Razoxane Phase 3
14
homoharringtonine Phase 3 3628
15 Vitamins Phase 3
16
2-Aminopurine Phase 3
17 Trace Elements Phase 3
18 Antidotes Phase 3
19 Calcium, Dietary Phase 3
20 Hematinics Phase 3
21 Micronutrients Phase 3
22 Protective Agents Phase 3
23 6-methoxypurine arabinoside Phase 3
24 Adjuvants, Immunologic Phase 3
25 Neuroprotective Agents Phase 3
26 Liver Extracts Phase 3
27
Calcium Nutraceutical Phase 3 7440-70-2 271
28
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
29
Coenzyme M Approved, Investigational Phase 1, Phase 2 3375-50-6 598 23662354
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
32
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
33
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
34
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
37
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
38
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
40
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
41
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
44
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
45
Daunorubicin Approved Phase 1, Phase 2 20830-81-3 30323
46
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
47
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
50
Mercaptopurine Approved Phase 2 50-44-2 667490

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
2 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
3 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
4 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
5 Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients Active, not recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
6 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
7 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
8 A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy Not yet recruiting NCT05602194 Phase 3 Calaspargase Pegol-mknl;Pegaspargase
9 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
10 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
11 Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7) Completed NCT00684619 Phase 2 Nelarabine
12 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
13 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
14 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
15 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
16 A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway Recruiting NCT03422679 Phase 1, Phase 2 CB-103
17 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
18 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
19 A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Recruiting NCT05289687 Phase 2 Daratumumab / Hyaluronidase Injection
20 A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) Recruiting NCT04984356 Phase 1, Phase 2
21 Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma:Phase II Study Recruiting NCT05598593 Phase 2 cytarabine+thiotepa+ fludarabine + busulfan
22 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
23 Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors Recruiting NCT03678883 Phase 2 9-ING-41;Gemcitabine - 21 day cycle;Doxorubicin.;Lomustine;Carboplatin.;Nab paclitaxel.;Paclitaxel.;Gemcitabine - 28 day cycle;Irinotecan
24 A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia Recruiting NCT04128501 Phase 2 Azacitidine;Venetoclax
25 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
26 A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia Recruiting NCT05268003 Phase 2 Ponatinib;Venetoclax;Mini-hyper CVD
27 Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia Recruiting NCT05149378 Phase 2 Venetoclax combined with azacitidine regimen
28 A Prospective, Multi-Center Study to Evaluate the Efficacy and Safety of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia Patients Recruiting NCT05376111 Phase 2 Venetoclax, Azacitidine
29 Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL) Recruiting NCT05032183 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Leucovorin;Mercaptopurine;Mesna;Methotrexate;Prednisone;Vincristine
30 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
31 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Active, not recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
32 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT02484430 Phase 2 Sapanisertib
33 A Phase II Study to Evaluate Safety and Efficacy of CB-103 in Combination With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) Not yet recruiting NCT05464836 Phase 2 CB-103;Venetoclax
34 A PedAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia Not yet recruiting NCT05320380 Phase 1, Phase 2 Anti-CD123 ADC IMGN632;Cytarabine;Fludarabine Phosphate;Hydrocortisone Sodium Succinate;Liposome-encapsulated Daunorubicin-Cytarabine;Methotrexate;Prednisolone
35 Phase II Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART) Not yet recruiting NCT04972942 Phase 2 Daratumumab
36 A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia Suspended NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
37 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;acetaminophen;ranitidine;diphenhydramine
38 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
39 A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Terminated NCT02767934 Phase 2
40 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Terminated NCT02763384 Phase 2 BL-8040;Nelarabine
41 A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Terminated NCT00742495 Phase 1, Phase 2 Forodesine
42 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
43 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
44 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated NCT01483690 Phase 1, Phase 2 Decitabine;Vorinostat;Vincristine;Dexamethasone;Mitoxantrone;Pegaspargase;Methotrexate
45 A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma Withdrawn NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
46 Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors Completed NCT00640796 Phase 1 Chemotherapy
47 Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells Completed NCT04572308 Phase 1
48 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
49 A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma Completed NCT01403415 Phase 1 Dexamethasone;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Temsirolimus;Vincristine Sulfate
50 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone

Search NIH Clinical Center for Precursor T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for Precursor T-Cell Acute Lymphoblastic Leukemia

Anatomical Context for Precursor T-Cell Acute Lymphoblastic Leukemia

Organs/tissues related to Precursor T-Cell Acute Lymphoblastic Leukemia:

MalaCards : Bone Marrow, T Cells, Bone, Myeloid, Liver, Thymus, B Cells

Publications for Precursor T-Cell Acute Lymphoblastic Leukemia

Articles related to Precursor T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 4411)
# Title Authors PMID Year
1
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. 53 62
20516195 2010
2
Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. 53 62
20459861 2010
3
Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. 53 62
20155852 2010
4
Genetic inactivation of Ikaros is a rare event in human T-ALL. 53 62
19796813 2010
5
T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. 53 62
19631984 2010
6
Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. 53 62
19608273 2010
7
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. 53 62
20015880 2010
8
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. 53 62
20124220 2010
9
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 53 62
19559479 2010
10
Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia. 53 62
20374994 2010
11
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 53 62
20161710 2010
12
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 53 62
20093438 2010
13
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 53 62
20008304 2010
14
Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. 53 62
20208138 2010
15
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 53 62
20023257 2010
16
NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells. 53 62
19835636 2009
17
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 53 62
19564891 2009
18
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. 53 62
19635999 2009
19
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. 53 62
19357700 2009
20
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. 53 62
19340001 2009
21
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. 53 62
19458356 2009
22
WT1 mutations in T-ALL. 53 62
19494353 2009
23
Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. 53 62
19171877 2009
24
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. 53 62
19246562 2009
25
The mechanism of chemokine receptor 9 internalization triggered by interleukin 2 and interleukin 4. 53 62
19567201 2009
26
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. 53 62
19469710 2009
27
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. 53 62
19091404 2009
28
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. 53 62
19109228 2009
29
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 53 62
19245433 2009
30
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. 53 62
19318552 2009
31
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. 53 62
19351820 2009
32
[Functional analysis of notch in the pathophysiology of leukemia]. 53 62
19489437 2009
33
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. 53 62
19185842 2009
34
The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. 53 62
19055661 2009
35
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. 53 62
19001083 2009
36
The role of NOTCH1 signaling in T-ALL. 53 62
20008221 2009
37
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. 53 62
19778842 2009
38
CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. 53 62
18683236 2008
39
Notch1 is a frequent mutational target in chemically induced lymphoma in mouse. 53 62
18798262 2008
40
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. 53 62
18981238 2008
41
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. 53 62
18830414 2008
42
Relative expression of different Ikaros isoforms in childhood acute leukemia. 53 62
18675565 2008
43
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. 53 62
18835836 2008
44
[Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols]. 53 62
19176062 2008
45
[Comparative analysis of blast immunophenotype between the diagnosis and relapse of childhood acute lymphoblastic leukaemia - implications for monitoring of minimal residual disease]. 53 62
19531824 2008
46
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. 53 62
18677410 2008
47
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. 53 62
18765521 2008
48
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. 53 62
18577685 2008
49
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. 53 62
18411416 2008
50
Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution. 53 62
18617057 2008

Variations for Precursor T-Cell Acute Lymphoblastic Leukemia

Expression for Precursor T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for Precursor T-Cell Acute Lymphoblastic Leukemia.

Pathways for Precursor T-Cell Acute Lymphoblastic Leukemia

Pathways related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.82 TRB TRA MYC
2 11.4 MYC MYB CDKN2A
3 11.27 MYC MYB CDKN2A
4 10.67 MYC CDKN2A ABL1
5 10.54 TRB TRA
6
Show member pathways
10.43 MYC CDKN2A ABL1
7 10.1 MYC BCR ABL1

GO Terms for Precursor T-Cell Acute Lymphoblastic Leukemia

Cellular components related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alpha-beta T cell receptor complex GO:0042105 8.62 TRB TRA

Biological processes related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TLX1 TAL1 SALL2 MYC MYB MLLT10
2 regulation of somatic stem cell population maintenance GO:1904672 9.43 TAL1 MYC
3 T cell mediated cytotoxicity directed against tumor cell target GO:0002419 8.96 TRB TRA
4 detection of tumor cell GO:0002355 8.62 TRB TRA

Molecular functions related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.47 TLX3 TLX1 TAL1 SALL2 MYC MYB

Sources for Precursor T-Cell Acute Lymphoblastic Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....